Post-ASH 2022 Lymphoma & Chronic Lymphocytic Leukemia Highlights

Free-to-attend Virtual Workshop by VJHemOnc featuring presentations & discussions
on selected lymphoma & CLL abstracts from the 64^th ASH Annual Meeting

Thursday 19 January | 10:00–13:00 EST/ 15:00–18:00 GMT/ 16:00–19:00 CET

This event is for hematologists, researchers, nurses, and allied medical professionals only.
We will review your application and confirm your registration on submission.
By applying, you confirm that VJHemOnc can communicate with you regarding this event and share relevant hematology news.

Chairs:

John Gribben, London, UK
Loretta Nastoupil, Houston, USA
Barbara Eichhorst, Cologne, Germany

Draft Agenda (subject to change)

Session 1: Addressing unmet needs in lymphoma 

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase I/II Trial.
Lorenzo Falchi (611) 

Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma.
Yago Nieto (168) 

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase I/II Study.
Catherine Thieblemont (233) 

Panel discussion 

Session 2: Mantle-Cell Lymphoma 

Phase II Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma.
Jia Ruan (73)

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma.
Tycel J. Phillips (74)

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and BTKi-Refractory Disease: First Report of the Tarmac Study.
Adrian Minson (75)

Results from a Phase I/II Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma.
Nirav N. Shah (4198) 

Panel discussion

Session 3: Advances in CLL, SLL and Richter’s transformation 

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase III Study
Jennifer Brown (LBA-6)

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study.
Talha Munir (94)

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase I/II BRUIN Study.
William G. Wierda (347)

Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase Ib/II Trial (EPCORE CLL-1).
Arnon P. Kater (348) 

Panel discussion

Session 4: Key updates for CAR T in lymphoma (1)

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy.
Joanna Zurko (154)

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Jae H. Park (163)

Phase I Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30+ T-Cell Lymphoma: Clinical and Biological Studies.
Ana Carolina Caballero Gonzalez (164)

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma.
David H. Quach (167) 

Panel discussion

Key updates for CAR T in lymphoma (2)

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site.
Ulrike Gerdemann (165

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase II Lysa Study.
Roch Houot (166)

A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL).  

Caron A. Jacobson (440) 

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase III Transform Study.  

Manali Kamdar (655) 

Panel discussion  

Session 5: Treatment updates for (D)LBCL 

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update.
Pere Barba (439) 

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2.
Won-Seog Kim (444)
 

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment. 

Martin Hutchings (441) 

Panel discussion

END OF WORKSHOP

This event is for hematologists, researchers, nurses, and allied medical professionals only.
We will review your application and confirm your registration on submission.
By applying, you confirm that VJHemOnc can communicate with you regarding this event and share relevant hematology news.